IL2 and myeloid neoplasm: In this study, NK cells obtained from PBMCs of an HLA haploidentical related donor, after an overnight incubation with IL-2 were infused at escalating doses (dose ranging from 0.02 to 8.32 × 106/kg) in 21 high-risk myeloid malignancies.